Kinase inhibitors in CLL: drawing the roadmap

Nathan Fowler

doi:10.1182/blood.2020010052

Kinase inhibitors in CLL: drawing the roadmap

Nathan Fowler

Lymphoma-Myeloma

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	2717-2719
Number of pages	3
Journal	Blood
Volume	137
Issue number	20
DOIs	https://doi.org/10.1182/blood.2020010052
State	Published - May 20 2021

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2020010052

Cite this

@article{1f32be66ceda48eaad1e9b60af447a12,

title = "Kinase inhibitors in CLL: drawing the roadmap",

author = "Nathan Fowler",

note = "Funding Information: Conflict-of-interest disclosure: N.F. served on scientific advisory boards and received research funding from Gilead, TG Therapeutics, Janssen, Novartis, and Bristol Myers Squibb. ",

year = "2021",

month = may,

day = "20",

doi = "10.1182/blood.2020010052",

language = "English (US)",

volume = "137",

pages = "2717--2719",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "20",

}

TY - JOUR

T1 - Kinase inhibitors in CLL

T2 - drawing the roadmap

AU - Fowler, Nathan

N1 - Funding Information: Conflict-of-interest disclosure: N.F. served on scientific advisory boards and received research funding from Gilead, TG Therapeutics, Janssen, Novartis, and Bristol Myers Squibb.

PY - 2021/5/20

Y1 - 2021/5/20

UR - http://www.scopus.com/inward/record.url?scp=85106606487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106606487&partnerID=8YFLogxK

U2 - 10.1182/blood.2020010052

DO - 10.1182/blood.2020010052

M3 - Editorial

C2 - 34014294

AN - SCOPUS:85106606487

SN - 0006-4971

VL - 137

SP - 2717

EP - 2719

JO - Blood

JF - Blood

IS - 20

ER -

Kinase inhibitors in CLL: drawing the roadmap

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this